NCT04108962View on ClinicalTrials.gov

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 23, 2019

Primary Completion Date

September 24, 2021

Study Completion Date

October 1, 2021

Conditions
ABPASevere AsthmaAllergic Bronchopulmonary Aspergillosis
Interventions
DRUG

Fasenra, 30 Mg/mL Subcutaneous Solution

Anti-IL5 receptor alpha monoclonal antibody

Trial Locations (1)

75246

Baylor University Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER